Tevogen Bio announces its AI initiative, Tevogen.AI™, enhancing immunotherapy development through machine learning and predictive modeling.
Quiver AI Summary
Tevogen Bio Holdings Inc. has announced its new artificial intelligence initiative, Tevogen.AI™, aimed at enhancing its ExacTcell™ technology for improved target identification and preclinical processes related to immunotherapy development. This initiative includes patent-pending technologies, such as PredicTcell™ and AdapTcell™, which utilize advanced machine learning to optimize immunotherapy treatments and improve understanding of immune responses. Tevogen is collaborating with strategic partners like Microsoft and Databricks to leverage AI expertise and data analytics, with plans to further expand its operations and dedicate resources to AI development. CEO Dr. Ryan Saadi emphasized the transformative potential of Tevogen.AI across healthcare, aiming to accelerate clinical timelines, lower costs, and ultimately enhance patient outcomes. Tevogen remains committed to transparent communication with stockholders regarding its progress.
Potential Positives
- Tevogen.AI™ aims to integrate advanced AI technology into its existing ExacTcell™ platform, potentially enhancing the company's research capabilities and drug development processes.
- The company has established strategic partnerships with leading entities like Microsoft and Databricks, granting access to significant resources and expertise that could accelerate drug discovery.
- Tevogen.AI has developed two proprietary technologies, PredicTcell™ and AdapTcell™, with patents pending, indicating innovation and potential market value for the company.
- The expansion of Tevogen's headquarters to include dedicated facilities for AI development signals a commitment to growth and the potential for enhanced operational capabilities in the future.
Potential Negatives
- The press release emphasizes the company's reliance on forward-looking statements, which highlights uncertainty regarding future growth and operational success.
- The mention of potential capital raising needs suggests financial instability or challenges in executing the business plan.
- Concerns regarding the ability to manage growth and execute strategies effectively may point to underlying difficulties in scalability and operational management.
FAQ
What is Tevogen.AI™?
Tevogen.AI™ is an artificial intelligence initiative aimed at enhancing immunotherapy development using advanced machine learning and predictive modeling.
How will Tevogen.AI™ impact drug development?
Tevogen.AI™ is expected to accelerate clinical timelines, strengthen the product pipeline, and significantly reduce drug development costs.
What technologies are included in Tevogen.AI™?
Tevogen.AI™ currently includes two proprietary technologies: PredicTcell™ and AdapTcell™, both focused on improving immunotherapy precision.
Who are the strategic partners for Tevogen.AI™?
Strategic partners include Microsoft for AI expertise and cloud infrastructure, and Databricks for data engineering and analytics capabilities.
What are the future plans for Tevogen.AI™?
Tevogen plans to expand its AI initiative to encompass clinical trial patient identification and broader applications in healthcare.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TVGN Insider Trading Activity
$TVGN insiders have traded $TVGN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $TVGN stock by insiders over the last 6 months:
- NEAL FLOMENBERG (See Remarks) has made 0 purchases and 7 sales selling 658,694 shares for an estimated $735,675.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TVGN Hedge Fund Activity
We have seen 28 institutional investors add shares of $TVGN stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PORTLAND GLOBAL ADVISORS LLC removed 1,854,517 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,910,152
- POLAR ASSET MANAGEMENT PARTNERS INC. removed 1,577,387 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,624,708
- VANGUARD GROUP INC added 895,873 shares (+617.0%) to their portfolio in Q1 2025, for an estimated $967,542
- CANTOR FITZGERALD, L. P. removed 603,691 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $621,801
- BLACKROCK, INC. added 232,477 shares (+38.6%) to their portfolio in Q1 2025, for an estimated $251,075
- HGC INVESTMENT MANAGEMENT INC. removed 223,077 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $229,769
- NORTHERN TRUST CORP added 40,225 shares (+34.0%) to their portfolio in Q1 2025, for an estimated $43,443
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) --
Tevogen
(“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq:
TVGN
), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™.
Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio’s proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company’s pipeline of innovative immunotherapies, accelerating clinical timelines, and substantially reducing development costs.
Tevogen.AI currently has two proprietary technologies, each with patents pending, and an internal valuation of these assets is forthcoming. The Company plans to expand its AI initiative with applications that extend well beyond Tevogen Bio. In preparation for this anticipated growth, Tevogen is expanding its headquarters to include dedicated facilities for Tevogen.AI’s team of data scientists and engineers.
Tevogen CEO, Dr. Ryan Saadi, commented, “Healthcare is one of the largest segments of our economy, projected to approach $5 trillion in the U.S. in 2025 and a significant contributor to our rising national debt. Tevogen.AI’s vision extends beyond transforming how therapies are developed; it is expected to make a meaningful impact across multiple sectors of healthcare. I applaud the leadership team at Tevogen.AI and our strategic partners for their innovative efforts and contributions that will help define the future of healthcare.”
Strategic Partnerships:
Microsoft (Nasdaq:
MSFT
):
Provides industry-leading AI expertise, cloud computing infrastructure (Azure), and scientific resources to accelerate drug discovery processes.
Databricks:
Supplies specialized data engineering and analytics capabilities to refine Tevogen’s AI models and enhance predictive accuracy.
Proprietary Tevogen.AI Technology:
PredicTcell™:
AI tools capable of accurately predicting immunologically active peptide complexes and their interactions with T cell receptors, driving precision in immunotherapy treatments.
The PredicTcell platform is a collection of multiple algorithms which performs in-silico predictions for candidate selection across multiple diseases. It continually improves with each accurate prediction through model tuning and reinforcement, helping expand our understanding of T cell receptor bindings, and therefore shortening the in-vivo process and expanding Tevogen Bio’s pipeline. To date, Tevogen.AI has developed a continually expanding, terabyte-scale database that processes millions of protein and peptide interactions spanning numerous diseases and the human genome.
AdapTcell™:
Algorithms to decode the interactions between human leukocyte antigens (HLA) and T cells.
AdapTcell is expected to significantly enhance Tevogen Bio’s understanding of immune responses and open new therapeutic avenues, especially in areas with minimal existing data. As our understanding of key interactions expand, AdapTcell built algorithms perform experiments unlocking insights into genetics and proteomics. The platform aims to expand upon the cross sections of genetics and protein interactions and build an HLA specificity map.
Tevogen.AI plans to expand into clinical trial patient identification using the information collected from its PredicTcell and AdapTcell platforms to drive efficiency, cost reduction and deliver targeted results.
Tevogen remains committed to transparent communication with its stockholders and will continue providing clear updates on the progress and achievements of Tevogen.AI.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
